Navigation Links
Leading Immunologists Convene in Boston
Date:6/2/2008

Annual meeting of the Federation of Clinical Immunology Societies opens June 5

BOSTON, June 2 /PRNewswire-USNewswire/ -- Over a thousand scientists and clinicians will convene to present new advances in understanding and treating immune-mediated diseases at FOCIS 2008, the 8th annual meeting of the Federation of Clinical Immunology Societies (FOCIS), June 5-9 at the Boston Marriott Copley Place.

Conference participants will present new research findings for conditions in which the human immune system plays a significant role, such as Multiple Sclerosis, cancer, allergy and asthma, diabetes, inflammatory bowel disease, and AIDS. The topics and speakers will address underlying immune pathogenesis, novel therapies and shared insights on topics such as new mechanisms and therapeutic targets, innovations in genetic approaches and how inflammatory regulators communicate danger.

In contrast to traditional medical meetings which focus on particular medical specialties, the FOCIS approach is to highlight and probe the underlying common elements of diseases which can lead to better therapies. "As the immunology field rapidly advances in clinical trials and the introduction of new and specific immunotherapies the opportunity to share knowledge and speed progress has never been greater," says Dr. Jerry Nepom, MD, PhD, Director of the Benaroya Research Institute at Virginia Mason, Seattle, Wash. and president of FOCIS.

"Today, immunology represents a critical pathway to unlock answers to treat many of today's diseases. To that end, it is important to broaden the access to educational programs to further immunological knowledge for investigators, basic scientists and clinicians. The FOCIS annual meeting provides a forum for this timely exchange. This meeting brings special value by translating knowledge from basic science into multiple clinical disciplines to both understand and treat immune-based diseases," Nepom said.

Nepom says the tra
'/>"/>

SOURCE Federation of Clinical Immunology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
4. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
5. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
6. Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection
7. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
8. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
9. Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Dont Vaccinate
10. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
11. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)..., , INDIANAPOLIS, Dec. 4 /PRNewswire-...ion (FDA) today approved Zyprexa® (olanzapine... schizophrenia and manic or mixed episodes associa...-17 years old. ,, The updated Zyprexa label st...n the increased potential for weight gain and hype...
(Date:12/4/2009)..., , OMAHA, Neb., Dec. 4 Am...editation by the Accreditation Commission for Heal...ices. For nearly 15 years, Amber Pharmacy has prov...ices to meet the unique needs of specialized condi...ers of services to transplant programs. They work ...
(Date:12/4/2009)..., , STREAMWOOD, Ill., Dec. 4 /PRNewswire/...f CT, MRI and PET/CT systems and service programs ... to announce it has received The Joint Commission,...onally-recognized, prestigious gold seal of approv...Imaging accreditation is system-wide for its mobil...
Breaking Medicine Technology:FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Amber Pharmacy Earns Accreditation From ACHC 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2Gut worms may protect against house dust mite allergy 58400 1Gut worms may protect against house dust mite allergy 58400 2Gut worms may protect against house dust mite allergy 58400 3Penn studies point to strategies for reducing painful breast cancer drug side effects 58396 1Penn studies point to strategies for reducing painful breast cancer drug side effects 58396 2Penn studies point to strategies for reducing painful breast cancer drug side effects 58396 3Canker disease in eucalyptus in the Basque Country 10128 1Canker disease in eucalyptus in the Basque Country 10128 2Canker disease in eucalyptus in the Basque Country 10128 3Canker disease in eucalyptus in the Basque Country 10128 4
... ANTIPOLIS, France, Nov. 7 NicOx S.A.,(Eurolist: ...xploratory,pharmacodynamic study for naproxcinod u...ere presented yesterday at the American Heart,Asso...ida. Naproxcinod is,the first compound in the COX-...ammatory agents and is in clinical development for...
..., Nov. 7 Vital Therapies, Inc. (VTI), announced,t...) (Extracorporeal Liver,Assist Device) System were...e Study of Liver Diseases (AASLD) Annual Meeting, ...Abstract (#91), "Interim results of Randomized Con...Liver Disease," was presented in a parallel s...
Other Medicine Technology:NicOx' Naproxcinod ABPM Data Presented at American Heart Association 2NicOx' Naproxcinod ABPM Data Presented at American Heart Association 3NicOx' Naproxcinod ABPM Data Presented at American Heart Association 4Vital Therapies Announces Presentation of ELAD(R) 'Artificial Liver' Data at American Association for the Study of Liver Diseases 2007 Annual Meeting 2
(Date:12/4/2009)...irstCall/ -- Care Investment Trust Inc. (NYSE: ...hat its Board of Directors has declared a dividend... is payable on December 22, 2009 to common shareho...out Care Investment Trust ,, Care Investment T...company investing in healthcare-related real estat...
(Date:12/4/2009)...swire/ -- Medithrive, Inc. has won the Patient,s C...ay Area by popular vote conducted by the online we...hs in operation, the SF Bay community has selected...ng medicinal marijuana. ,, The rapid rise and...dispensary which caters to the consumer, provides ...
(Date:12/4/2009)...-USNewswire/ -- The American Association of Homes ...nate for ensuring that the Community Living and S...e final health reform legislation . The CLASS prov...rs, people with disabilities and their caregivers....eform bill that will make it affordable to care fo...
(Date:12/4/2009)...Newswire/ -- The large, two-day free health clinic...nics (NAFC) in Kansas City on Wednesday and Thursd...o is uninsured and has not seen a doctor recently....e preventive primary care. ,, "Many people who...nts this fall in Houston, New Orleans and Little R...
(Date:12/4/2009)...Newswire/ -- Pamela Bowen, Chief Information Offic...ist for the "Chief Innovation Officer" Appy Award ...r of cloud computing. Appy Award recipients are no...rce CRM or the Force.com platform in bringing new ...ng, partner, service, support or IT organizations....
Breaking Medicine News(10 mins):Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Free Health Clinic Event Is Not Just for the Sick 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2
..., The Association for Gerontology in Higher Educ...ntological Society of America , will hold its 35t...ence February 26March 1, 2009, at the Crowne Pla... about gerontological and geriatric education and ...
..., CARLSBAD, Calif., Jan. 30 Beautiful skin wi...you may actually save money on skin care,this year...tress level and,cleaning out your cabinets. , ...skin. With the ten thrifty tips, this host of "Ski...
..., RED BANK, New Jersey, BRUSSELS and MELBOURNE...obal corporate,website. With over a century of exp...otective solutions is now rethinking its presence ... The site includes corporate information with ...
..., Three New Studies Initiated in Other Oncology Se...0 GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN)...ense Application (BLA) to the U.S. Food and Drug A...erapies. If approved, ofatumumab would be the firs...
..., SAN DIEGO and LISLE, Ill., Jan. 30 SpineMar...that partners with hospitals and,physicians to dev... a,partnership with Healthplace America to deliver...Surgery Benefit(TM). As a result,of their affilia...
..., MIAMI, Jan. 30 Physicians Healthcare Managemen...developer of health maintenance organizations (HMO...hyshield Insurance Exchange, a licensed medical ma...ongress and a new administration in Washington. H...
Other Medicine News:Health News:Teaching about financial crisis among Gerontology Meeting's highlights 2Health News:Ten Thrifty Tips for Radiant Skin 2Health News:Ten Thrifty Tips for Radiant Skin 3Health News:Ansell Limited Launching a New Global Website 2Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 2Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 3Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 4Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 5Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 6Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 7Health News:GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer 8Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 2Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 3Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 4Health News:Phyhealth Provides Update to Shareholders 2Health News:Phyhealth Provides Update to Shareholders 3Health News:Phyhealth Provides Update to Shareholders 4
AGC Revision knee
Advance Stemmed Medial-Pivot Knee
AGC Dual Articular Knee
Scorpio TS Single Axis Revision Knee System
Medicine Products: